Masamichi Sugimoto

2.1k total citations
45 papers, 1.7k citations indexed

About

Masamichi Sugimoto is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Masamichi Sugimoto has authored 45 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 19 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Masamichi Sugimoto's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Glycosylation and Glycoproteins Research (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Masamichi Sugimoto is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Glycosylation and Glycoproteins Research (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Masamichi Sugimoto collaborates with scholars based in Japan, United States and Switzerland. Masamichi Sugimoto's co-authors include Kazuyuki Yoshizaki, Norihiro Nishimoto, Hideko Nakahara, Tadamitsu Kishimoto, Keisuke Hagihara, Jian Song, Ernst B. Hunziker, Shigeto Kawai, Akito Nakamura and Makoto Okazaki and has published in prestigious journals such as The Journal of Immunology, Cancer Research and Scientific Reports.

In The Last Decade

Masamichi Sugimoto

44 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masamichi Sugimoto Japan 19 526 506 465 365 200 45 1.7k
Daisuke Goto Japan 26 353 0.7× 302 0.6× 663 1.4× 945 2.6× 170 0.8× 105 2.0k
Hans P. Kiener Austria 29 677 1.3× 336 0.7× 803 1.7× 700 1.9× 146 0.7× 51 2.2k
Koji Yoshida Japan 26 848 1.6× 909 1.8× 176 0.4× 549 1.5× 149 0.7× 106 2.4k
Dirk Pohlers Germany 17 552 1.0× 228 0.5× 423 0.9× 211 0.6× 138 0.7× 26 1.4k
So‐Young Bang South Korea 24 442 0.8× 160 0.3× 846 1.8× 593 1.6× 174 0.9× 100 1.8k
Takahiko Aoyagi Japan 23 541 1.0× 284 0.6× 323 0.7× 296 0.8× 69 0.3× 50 1.3k
Huaxia Yang China 22 393 0.7× 609 1.2× 471 1.0× 414 1.1× 102 0.5× 64 1.6k
Birgitte Walgreen Netherlands 18 405 0.8× 257 0.5× 624 1.3× 529 1.4× 170 0.8× 52 1.4k
Hirofumi Shoda Japan 23 450 0.9× 432 0.9× 515 1.1× 1.1k 3.0× 205 1.0× 100 2.0k
Gianluigi Arrigoni Italy 23 634 1.2× 696 1.4× 248 0.5× 524 1.4× 94 0.5× 59 2.4k

Countries citing papers authored by Masamichi Sugimoto

Since Specialization
Citations

This map shows the geographic impact of Masamichi Sugimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masamichi Sugimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masamichi Sugimoto more than expected).

Fields of papers citing papers by Masamichi Sugimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masamichi Sugimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masamichi Sugimoto. The network helps show where Masamichi Sugimoto may publish in the future.

Co-authorship network of co-authors of Masamichi Sugimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Masamichi Sugimoto. A scholar is included among the top collaborators of Masamichi Sugimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masamichi Sugimoto. Masamichi Sugimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yorozu, Keigo, et al.. (2024). PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model. Clinical & Experimental Metastasis. 41(6). 909–924. 3 indexed citations
2.
Mitsuhashi, Atsushi, Kazuya Koyama, Hirokazu Ogino, et al.. (2023). Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Reports. 42(3). 112162–112162. 12 indexed citations
3.
Pan, Cheng, Yukio Fujiwara, Yoshihiro Komohara, et al.. (2023). Dysfunction of sinus macrophages in tumor‐bearing host induces resistance to immunotherapy. Cancer Science. 115(1). 59–69. 6 indexed citations
4.
Wakita, Daiko, et al.. (2021). PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion. Clinical & Experimental Metastasis. 39(2). 335–344. 2 indexed citations
5.
Wakita, Daiko, Toshiki Iwai, Suguru Harada, et al.. (2019). Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Anticancer Research. 39(4). 1749–1760. 35 indexed citations
6.
Ishikura, Nobuyuki, Mieko Yanagisawa, Toshiki Iwai, et al.. (2017). Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models. Anticancer Research. 37(2). 623–630. 6 indexed citations
7.
8.
Sano, Yuji, Eri Hashimoto, Noriaki Nakatani, et al.. (2014). Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression. Molecular Cancer Therapeutics. 14(2). 533–541. 22 indexed citations
9.
Ishiguro, Takahiro, Yasuko Kinoshita, Masamichi Sugimoto, et al.. (2010). Abstract 2426: Anti-Glypican3 antibody for treatment of human liver cancer. Cancer Research. 70(8_Supplement). 2426–2426. 2 indexed citations
10.
TAKAI, H., Atsuhiko Kato, Takahiro Ishiguro, et al.. (2009). Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. Acta Histochemica. 112(3). 240–250. 18 indexed citations
11.
Orita, Tetsuro, Jun‐ichi Nezu, Takeshi Yoshino, et al.. (2008). Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications. 378(2). 279–284. 91 indexed citations
12.
Ishiguro, Takahiro, Masamichi Sugimoto, Yasuko Kinoshita, et al.. (2008). Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer. Cancer Research. 68(23). 9832–9838. 135 indexed citations
13.
Kurth, Tobias B., Erik Hedbom, Nahoko Shintani, et al.. (2007). Chondrogenic potential of human synovial mesenchymal stem cells in alginate. Osteoarthritis and Cartilage. 15(10). 1178–1189. 127 indexed citations
14.
Mihara, Masahiko, Makoto Okazaki, Akito Nakamura, et al.. (2005). Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. International Immunopharmacology. 5(12). 1731–1740. 258 indexed citations
15.
Kimura, Naoki, Shigeto Kawai, Yasuko Kinoshita, et al.. (2004). 2D7 diabody bound to the α2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells. Biochemical and Biophysical Research Communications. 325(4). 1201–1209. 8 indexed citations
16.
Nakahara, Hideko, Jian Song, Masamichi Sugimoto, et al.. (2003). Anti–interleukin‐6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis & Rheumatism. 48(6). 1521–1529. 323 indexed citations
17.
Tsumaki, Noriyuki, Masamichi Sugimoto, Ken Nakata, et al.. (1996). Separable Regulatory Elements from Pro‐α2(XI) Collagen Gene Drive Distinct Patterns of Cartilage‐Specific Expression in Transgenic Mice. Annals of the New York Academy of Sciences. 785(1). 340–342. 2 indexed citations
18.
Higuchi, Masahiro, Masamichi Sugimoto, Yoshiro Kobayashi, & Toshiaki Osawa. (1987). Human Macrophage‐Activating Factors for Cytotoxicity. Microbiology and Immunology. 31(5). 481–490. 3 indexed citations
19.
Takeda, Yasuhisa, et al.. (1985). Purification and characterization of a cytotoxic factor produced by a mouse macrophage hybridoma. Cellular Immunology. 96(2). 277–289. 14 indexed citations
20.
Sugimoto, Masamichi, Yoshihiro Wakabayashi, Yoshiaki Shiokawa, & F Takaku. (1981). Immunological studies on the nature of anemia in rheumatoid arthritis and leukopenia in systemic lupus erythematosus.. PubMed. 21 Suppl. 51–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daisuke Goto Breakdown of academic impact, for papers by Hans P. Kiener Breakdown of academic impact, for papers by Koji Yoshida Breakdown of academic impact, for papers by Dirk Pohlers Breakdown of academic impact, for papers by So‐Young Bang Breakdown of academic impact, for papers by Takahiko Aoyagi Breakdown of academic impact, for papers by Huaxia Yang Breakdown of academic impact, for papers by Birgitte Walgreen Breakdown of academic impact, for papers by Hirofumi Shoda Breakdown of academic impact, for papers by Gianluigi Arrigoni
Rankless by CCL
2026